Overview

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Status:
Completed
Trial end date:
2019-02-21
Target enrollment:
Participant gender:
Summary
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Biopharma S.P.R.L.
Treatments:
Adalimumab